<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <title>Submission 300 from Anon (session_user_id: f0e25b567367dc7a5721561e8933a2ada7ff949c)</title>
    <link href="../../../export.css" rel="stylesheet">
  </head>
  <body>
    <h1>Submission 300 from Anon (session_user_id: f0e25b567367dc7a5721561e8933a2ada7ff949c)</h1>
    <div class="field-name" id="d6002606a5ec3d03">Q1. Describe how DNA methylation is altered in cancer.
In your answer include the following points:
<br><p></p><ul><li>Describe the normal
function of DNA methylation at CpG islands.<br></li><li>Describe how DNA
methylation of CpG islands is disrupted in cancer.<br></li><li>Explain how disruption of
DNA methylation at CpG islands contributes to cancer.<br></li><li>Describe the normal
function of DNA methylation in intergenic regions and repetitive elements.<br></li><li>Describe how DNA
methylation in intergenic regions and repetitive elements is disrupted in cancer.<br></li><li>Explain how disruption
of DNA methylation in intergenic regions and repetitive elements contributes to
cancer.<br></li></ul><p></p></div>
    <div class="field-value"><p><span>Hypermethylation is one of the major epigenetic modifications
that repress the transcription process via promoter region of tumor suppressor genes.
Hypermethylation typically occurs at CpG islands in the promoter region and is
associated with gene inactivation. In normal
cells, CpG islands are hypomethylated, allowing gene transcription while the intergenic
regions, introns and repetitive<br /> elements are hypermethylated.
In cancer cells, by contrast, CpG islands are
strongly methylated and the intergenic regions, introns and repetitive elements are
hypomethylated. As a result, transcription of
many genes gets blocked, and aberrant transcription occurs. For the CpG islands, this leads to problem as tumor suppressor genes may become silenced,<br />allowing the cell to divide more rapidly, outcompete its neighboring cells, and grow into a tumour. For the latter<br />regions, normally hypermethylation at these sites is associated with greater genomic stability, so hypomethylation during <br />
cancer leads
to copying errors such as deletions, insertions and reciprocal translocations in the
chromosomes.</span></p>

<p> <a href="https://en.wikipedia.org/wiki/DNA_methylation">https://en.wikipedia.org/wiki/DNA_methylation</a> </p></div>

    <div class="field-name" id="961ab4c640df430a">Q3. The Economist article “<a href="http://www.economist.com/node/21552168" target="_blank">Cancer’s epicentre</a>” describes several drugs that affect
    epigenetic processes. Explain how Decitabine may be used to treat cancer,
    with reference to effects on the epigenome. In your answer include the
    following points:
<br>
<p></p>
    <ul>
        <li>Identify the class of epigenetic inhibitors that Decitabine belongs to.&nbsp;
            <br>
        </li>
        <li>Describe the impact of Decitabine on DNA methylation.
            <br>
        </li>
        <li>Describe how Decitabine can have an anti-tumour effect.&nbsp;
            <br>
        </li>
    </ul></div>
    <div class="field-value"><p><span><a href="http://chemocare.com/chemotherapy/drug-info/decitabine.aspx" title="Link: http://chemocare.com/chemotherapy/drug-info/decitabine.aspx">http://chemocare.com/chemotherapy/drug-info/decitabine.aspx</a> Decitabine belongs to the class of DNA methyltransferase inhibitors, and
contributes to the hypomethylation of DNA. It is useful in treating myelodysplatic
syndrome (a condition under which the bone marrow produces deformed blood cells)<br />which is a precursor of acute myelogenous leukemia.</span></p>

<p><span>Methylation
of DNA is a major mechanism that regulates gene expression in cells.  When
there is an increase in DNA methylation this can result in the blockage of the
activity of "suppressor genes" that regulate cell division and
growth.  When suppressor genes are blocked, cell division becomes
unregulated, allowing or promoting cancer. Decitabine works by
demethylation or interfering with the methylation of DNA. By this process
of demethylation, normal function to the tumor suppressor genes is restored,
thus restoring control over cell growth.
In case of Decitabine, the anti­tumour effect has
been linked to reactivation of epigenetically silenced <br />tumor supressor genes, induced by the
hypothemylation.</span></p></div>

    <div class="field-name" id="323cdd9789545f83">Q2. Describe how disruption of imprinting can contribute to cancer, using the example of the H19/Igf2 cluster. In your
answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe the methylation pattern of the paternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe the methylation pattern of the maternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe how imprinting at the H19/Igf2 cluster is disrupted in Wilm’s tumour.&nbsp;
        <br>
    </li>
    <li>Explain how disrupting imprinting at the H19/Igf2 cluster contributes to cancer.
        <br>
    </li>
</ul></div>
    <div class="field-value"><span>In a cell around the H19/Igf2 locus we normally see the methylation of the paternal allele at the
ICR, and no<br />methylation of the maternal allele. While
the CTCF complex binds to the allele on the
maternal strand, the downstream <br />enhancers act on H19 as a result
of which, the CTCF complex does not bind to the paternal allele due to<br />its methyl marks, which leads to silencing of the H19
gene and as the enhancers instead drive the expression of Igf2. <br />Thus, in a regular cell we observe a
normal dose of both H19 from maternal strand, and Igf2 from paternal strand. However, when
this ICR becomes hypermethylated, both strands appear to be of paternal origin and get
expressed as such.That is, the <br />system gets a double dose of (growth­promoting) Igf2 (as well
as no dose of H19). This is associated with Wilm's tumour.</span></div>

    <div class="field-name" id="10aa9d89e69a5f7a">Q4. Dr Stephen Baylin speculates in the Economist article that "epigenetic
drugs altered the tumour cells in some lasting way that made them more
susceptible to standard chemotherapy." How can drugs that alter DNA methylation
have effects that last beyond the period of drug treatment? Discuss whether
there are any periods of development when you would avoid treating patients
with such drugs. In your answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe how altering DNA methylation can have enduring effects on the
        epigenome.
        <br>
    </li>
    <li>Define what is meant by a sensitive period.
        <br>
    </li>
    <li>Identify sensitive periods of development.
        <br>
    </li>
    <li>Explain why treating patients during sensitive periods would be inadvisable.
    <br>
</li>
</ul></div>
    <div class="field-value"><span>DNA methylation is a particularly attractive form of regulation to target in treatments because it can be manipulated once,and<br />enduring effects are ensured as the DNA methyltransferase
enzymes preserve methyl marks during mitosis. </span>However, these <br />global interventions may
interfere with ordinary functioning of the system, especially during critical periods periods of
time<br />where extensive epigenetic reprogramming occurs. In particular, it would be inadvisable to
prescribe these treatments to<br />pregnant mothers (including a few months before conception) as
a lot of reprogramming happens in early child development <br />as well as during the formation of gametes (both male and female).</div>
  </body>
</html>